Economic data for IBB
Full calendarRecently released
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%
- TodayUSDCPI●●●Forecast 338.683Previous 336.298
Coming up
- November 12, 2026USDInitial Jobless Claims●●●in 1 day
- November 12, 2026USDEIA Crude Oil Stocks Change●●●in 2 days
- November 13, 2026USDCore PPI m/m●●●Forecast 0.4%Previous 0.7%in 2 days
- November 13, 2026USDPPI m/m●●●Forecast 0.4%Previous 1.3%in 2 days
- November 17, 2026USDCore Retail Sales m/m●●●Forecast 0.7%Previous 0.9%in 6 days
- November 17, 2026USDRetail Sales m/m●●●Forecast 0.3%Previous 0.8%in 6 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
IBB fundamental outlook
From news analysis — different time windows than the trading horizons above · as of 06.08.2026
- Braveheart Biotech's $382.5 million upsized IPO on August 6 signals strong institutional demand for biotech.
- Biotech IPOs are outperforming AI listings in 2026, leading the US stock rally per Bloomberg on July 21.
- Cellares's $50 million pre-IPO funding on June 15 indicates sustained investor interest in biotech automation.
- Parabilis's $745 million IPO on June 10 boosted biotech sector visibility and potential ETF inflows.
- Molecular glue deals surpassed $1 billion as of May 29, driving a sector-wide re-rating in targeted protein degradation.
- All six recent signals are bullish, with impact scores up to 9 and confidence up to 90, indicating strong momentum.
The iShares Biotechnology ETF (IBB) is riding a wave of bullish sentiment driven by a series of strong biotech IPOs and sector-specific breakthroughs. The most recent catalyst is Braveheart Biotech's upsized $382.5 million IPO on August 6, signaling robust institutional demand and healthy risk appetite for biotech. This follows a July 21 Bloomberg report that biotech IPOs are outperforming AI listings, leading the 2026 US stock rally and directly benefiting IBB. Earlier, on June 15, Cellares secured a $50 million pre-IPO investment, highlighting sustained investor interest in biotech automation. On June 10, Parabilis's $745 million IPO further boosted sector visibility. A June 2 article on Ebola cure research underscored the sector's innovative potential, while a May 29 report on molecular glue deals surpassing $1 billion cemented a structural growth narrative in targeted protein degradation. All six signals are bullish, with impact scores ranging from 3 to 9 and confidence from 55 to 90. The consistency and recency of these catalysts suggest strong momentum for IBB, though risks include potential post-IPO underperformance, regulatory hurdles, and macroeconomic shifts away from growth sectors. Overall, the biotech sector is experiencing a capital influx and positive news flow that should support IBB across multiple timeframes.
96 days ago · Based on 6 signals
📝 Overview Generated automatically
IBB has been the subject of 6 signals across 6 articles in the last 365 days. Sentiment skews Bullish (100%).
Breakdown: 6 bullish, 0 bearish, 0 neutral.
Most-cited catalysts: Sector-wide re-rating as more molecular glue deals are announced, boosting investor appetite for biotech stocks. (1×), Strong fundraising and partnership activity in the targeted protein degradation space indicates robust growth ahead. (1×), Positive news flow on antibody therapy development could boost biotech sector sentiment. (1×). Most-cited risk factors: Macroeconomic headwinds or a shift away from risk-on sentiment could hurt biotech ETFs regardless of fundamental progress. (1×), If molecular glue hype fades due to clinical setbacks, the entire biotech sector may face a pullback. (1×), Biotech sector is volatile and driven by larger macro trends. (1×).